Authors
Teck Chee Cheng, Khai Voon Ng, Jemaima Che Hamzah
Published in
Clinical ophthalmology (Auckland, N.Z.). Volume 20. Pages 605606. Epub Jul 10, 2026.
Abstract
To evaluate the one-year clinical outcomes, safety profile, and surgical success of the PreserFlo® MicroShunt in patients with glaucoma treated at a tertiary referral centre in Malaysia.
This retrospective study included 40 eyes of 31 patients undergoing PreserFlo MicroShunt implantation performed by two experienced surgeons using a standard ab-externo technique with mitomycin C (0.04% for 3 minutes) and a structured postoperative corticosteroid tapering regimen. Outcomes assessed at 12 months included intraocular pressure (IOP), number of topical glaucoma medications, visual acuity, optic nerve and retinal nerve fibre layer parameters, visual field indices, complications, and surgical success. Complete success was defined as achieving target IOP without medications, while qualified success allowed adjunctive medications.
Mean IOP was reduced from a preoperative median of 19.0 mmHg to 11.5 mmHg at 12 months (p < 0.001). The median number of glaucoma medications decreased from 3.8 to 0.2 drops. At one-year, complete surgical success was achieved in 82.5% of eyes, while qualified success was 95.0%. Surgical failure occurred in 5.0% of eyes. Early postoperative hypotony (IOP ≤5 mmHg) occurred in 17.5%, with persistent hypotony at one year in 2.5%, none of which resulted in vision loss. No cases of sight-threatening complications such as endophthalmitis, corneal decompensation, or loss of light perception were observed. Structural and functional glaucoma parameters remained stable over the follow-up period. Postoperative interventions were required in a proportion of eyes during follow-up.
PreserFlo MicroShunt implantation was associated with reductions in IOP and glaucoma medication burden at one year, with generally acceptable short-term safety outcomes. These findings support its role as an effective bleb-forming minimally invasive glaucoma surgery option for patients requiring lower target IOPs, including those with advanced glaucoma. However, the results should be interpreted in the context of the modest sample size, retrospective design, absence of a comparator group, and need for postoperative interventions. This study provides the first Malaysian real-world data on PreserFlo MicroShunt outcomes and adds to the growing regional evidence base for its use.
PMID:
42454273
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0